Alkermes Commences Arbitration Related to License Agreements with Janssen PharmaceuticaPRNewsWire • 04/19/22
Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research SocietyPRNewsWire • 04/07/22
Alkermes (ALKS) Up 2.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/18/22
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's CancerPRNewsWire • 03/01/22
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney CancerBenzinga • 02/17/22
Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers SymposiumPRNewsWire • 02/17/22
Alkermes plc. (ALKS) CEO Richard Pops on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/16/22
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022PRNewsWire • 02/16/22
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With SchizophreniaBenzinga • 02/08/22
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in IllnessPRNewsWire • 02/08/22
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/03/22
Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022PRNewsWire • 02/02/22
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers SymposiumPRNewsWire • 01/18/22
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment JourneyPRNewsWire • 01/06/22